欧洲监管者建议BeiGene的Tevimbra治疗成人常见的鼻喉癌。 European regulator recommends BeiGene's Tevimbra for treating recurrent nasopharyngeal cancer in adults.

BeiGene的癌症治疗Tevimbra接受了欧洲药品机构的一项积极建议,供经常患有鼻喉癌的成年人使用。 BeiGene's cancer treatment, Tevimbra, received a positive recommendation from the European Medicines Agency for use in adults with recurrent nasopharyngeal cancer. 这是今年对Tevimbra的第二项积极建议。 This is the second positive recommendation for Tevimbra this year. 鼻癌会影响鼻子后面的上喉部. Nasopharyngeal cancer affects the upper throat behind the nose. 这种治疗如果获得批准,将与其他药物结合使用,作为欧洲联盟合格病人的第一线选择。 The treatment, if approved, will be used in combination with other drugs as a first-line option for eligible patients in the European Union.